Branford and colleagues have reported on the development of resistance to imatinib mesylate in patients with chronic myeloid leukemia (CML) and with Ph+ acute lymphoblastic leukemia (ALL) treated with this drug. Their report highlights the biologic interest of this phenomenon, which, at the same
No takes yet. Share an insight, caveat, or question.
Luzzatto et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: